Low dose estrogen interrupted hormone replacement therapy

Details Low dose estrogen interrupted hormone replacement therapy Low dose estrogen interrupted hormone replacement therapy

2006-05-24

2008-01-22

Badio, Barbara P. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

07320970

ABSTRACT:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.

REFERENCES:
patent: 4957119 (1990-09-01), De Nijs
patent: 5088505 (1992-02-01), De Nijs
patent: 5108995 (1992-04-01), Casper
patent: 5256421 (1993-10-01), Casper
patent: 5276022 (1994-01-01), Casper
patent: 5382573 (1995-01-01), Casper
patent: 5422119 (1995-06-01), Casper
patent: 5585370 (1996-12-01), Casper
patent: 5633242 (1997-05-01), Oettel et al.
patent: 6133251 (2000-10-01), Dittgen et al.
patent: 6747019 (2004-06-01), Casper et al.
patent: 7078394 (2006-07-01), Casper et al.
patent: 44 29 374 (1996-02-01), None
patent: 0 275 716 (1988-07-01), None
patent: 0 309 263 (1989-03-01), None
patent: 0 770 388 (1997-05-01), None
patent: WO 97/11680 (1997-04-01), None
patent: WO 98/37897 (1998-09-01), None
Lobo, et al., “A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17β-estradiol on lipid and lipoprotein profiles,” Am J. of Obstet. & Gynecol., vol. 182, Jan. 2000, pp. 41-49 (XP-000900454), Elsevier B.V.
Sulak, et al., “Efficacy and Safety of a Constant-Estrogen, Pulsed-Progestin Regimen in Hormone Replacement Therapy,” Int'l Journal of Fertility and Women's Medicne, Nov.-Dec. 1999, pp. 286-296 (XP-000934379), MSP International, Inc.
Vanin, et al., “Lumbar vertebral density and mechanical properties in aged ovariectomized rats treated with estrogen and norethindrone or norgestimate,” Am. J. of Obstet. & Gynecol., vol. 173, 1995, pp. 1491-1498 (XP-000934383), Elsevier B.V.
Christin-Matrie, et al., “Perceptives de la contraception,” La Revue du Practicien, 1995, pp. 2449-2453 (English abstract on p. 2453 (last page)), Huveaux PLC.

Affiliated with

Also associated with

Rating

Low dose estrogen interrupted hormone replacement therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low dose estrogen interrupted hormone replacement therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low dose estrogen interrupted hormone replacement therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3963666